1 comment by Mikail

  • Thank you for this great overview of chemogenetics. As you have referred to in the article there is enormous potential in the clinical use of DREADDs and other chemogenetic technologies. I would like to draw your attention to our recently published work showing that the neuroleptic drug olanzapine is a potent DREADD activator (DOI: 10.1126/sciadv.aaw1567). Since it is already clinically approved this combination is currently the most promising for treating diseases such as epilepsy. We further discuss the principal designer receptor technologies for epilepsy in a review published this month (DOI: 10.1016/j.ebiom.2019.04.059).

    Commented on:22 May 2019 15:43

    An image showing scientists replacing locks on a membrane

    Changing the locks